Mycobacterial Disease Drug Development Needs Validated Clinical Outcome Assessment
Executive Summary
Experts at US FDA meeting debate tweaking components of existing measures to focus on symptoms – such as cough, fatigue and dyspnea – that are most bothersome to patients with the nontuberculous form of the disease.